These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 31227381

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis.
    Ito A, Ishida T, Tachibana H, Tokumasu H, Yamazaki A, Washio Y.
    Sci Rep; 2019 Dec 05; 9(1):18406. PubMed ID: 31804572
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M, Dadsetan B, Najafi Z, Jafari S, Mazaheri E, Dadras O, Heidari H, SeyedAlinaghi S, Voltarelli F.
    Recent Pat Antiinfect Drug Discov; 2018 Dec 05; 13(3):228-239. PubMed ID: 30360748
    [Abstract] [Full Text] [Related]

  • 5. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
    Frei CR, Jaso TC, Mortensen EM, Restrepo MI, Raut MK, Oramasionwu CU, Ruiz AD, Makos BR, Ruiz JL, Attridge RT, Mody SH, Fisher A, Schein JR.
    Curr Med Res Opin; 2009 Apr 05; 25(4):859-68. PubMed ID: 19231913
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
    Kyriazopoulou E, Sinapidis D, Halvatzis S, Velissaris D, Alexiou N, Kosmas V, Adami ME, Kyprianou M, Kyprianou A, Stefos A, Lada M, Koutoukas P, Pavlaki M, Kyriakoudi A, Makina A, Gogos C, Niederman MS, Giamarellos-Bourboulis EJ.
    Int J Antimicrob Agents; 2020 Jan 05; 55(1):105836. PubMed ID: 31704213
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ, Edwards KM, Self WH, Zhu Y, Arnold SR, McCullers JA, Ampofo K, Pavia AT, Anderson EJ, Hicks LA, Bramley AM, Jain S, Grijalva CG.
    JAMA Pediatr; 2017 Dec 01; 171(12):1184-1191. PubMed ID: 29084336
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
    Choi SH, Cesar A, Snow TAC, Saleem N, Arulkumaran N, Singer M.
    Int J Antimicrob Agents; 2023 Sep 01; 62(3):106905. PubMed ID: 37385561
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A, Ishida T, Tachibana H, Nakanishi Y, Tokioka F, Yamazaki A, Washio Y, Irie H, Otake T.
    J Infect Chemother; 2021 Oct 01; 27(10):1447-1453. PubMed ID: 34147355
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M, Mandell LA, Vrooman PS, Andrews CP, McIvor A, Abdulla RH, de Caprariis PJ, Knirsch CA, Amsden GW, Niederman MS, Lode H.
    Treat Respir Med; 2004 Oct 01; 3(5):329-36. PubMed ID: 15606222
    [Abstract] [Full Text] [Related]

  • 17. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F, Mensa J, Martínez JA, García E, Marco F, González J, Marcos MA, Soriano A, Torres A.
    Clin Infect Dis; 2003 May 15; 36(10):1239-45. PubMed ID: 12746768
    [Abstract] [Full Text] [Related]

  • 18. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP.
    Antimicrob Agents Chemother; 2007 Nov 15; 51(11):3977-82. PubMed ID: 17709460
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A, Ishida T, Tokumasu H, Washio Y, Yamazaki A, Ito Y, Tachibana H.
    BMC Pulm Med; 2017 May 02; 17(1):78. PubMed ID: 28464807
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.